MedPath

Active Removal of IntraCerebral Hematoma Via Active Irrigation

Not Applicable
Recruiting
Conditions
Cerebral Hemorrhage
Intraventricular Hemorrhage
Interventions
Device: IRRAflow
Device: EVD
Registration Number
NCT05118997
Lead Sponsor
IRRAS
Brief Summary

Study evaluating if active irrigation by IRRAflow® with infusion of tPA will reduce the time needed for clearance of intracerebral and intraventricular hemorrhage compared with passive drainage.

Detailed Description

The ARCH study is an international prospective, controlled, randomized, multicenter study to evaluate the hypothesis that active irrigation with IRRAflow® will reduce the time needed for clearance of intraventricular and intracerebral blood from intraventricular and intracerebral space compared with passive drainage and administration of tPA. This might affect the patient neurological outcome assessed by GCS and mRankin scale.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  1. Age >18 years of age

  2. Need of EVD

  3. Active treatment

  4. Signed informed consent obtained

    a. Based on institutional and country laws

  5. Spontaneous ICH with maximum 30 square cm's

  6. If needed, normal coagulation profile (PT, PTT, platelet count)

  7. Treatment within 72 hours of ictus

  8. Ability to administer 2.0 mg of tPA per day for 3 days

Exclusion Criteria
  1. Age < 18 years
  2. No need of EVD
  3. Patient has fixed and dilated pupils
  4. Coagulopathy uncorrectable
  5. Vascular pathology (e.g. Aneurysm involvement, AVM involvement)
  6. Pregnant women

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Arm && Interventions
GroupInterventionDescription
Treatment Arm #1IRRAflowIRRAflow with manual tPA administration followed by Active Fluid Exchange
Treatment Arm #2IRRAflowIRRAflow with continuous infusion of tPA combined with Active Fluid Exchange
Treatment Arm #3EVDStandard EVD with manual tPA administration
Primary Outcome Measures
NameTimeMethod
Efficacy and safety of evacuation of intraventricular hematoma by Active External Ventricular Drainage (IRRAflow) with tPA administration compared to Passive External Ventricular Drainage (EVD) with tPA administration.Intra-procedure

Efficacy is defined as the efficiency of each arm to remove the hematoma (70% cm3). Safety is measured as the frequency of bacterial central nervous system (measures as positive bacterial growth in cerebrospinal fluid), symptomatic brain bleeds (clinical symptoms drop in modified Rankin scale), and mortality (death).

Radiographic evaluation of ventricular blood removal as measured by head CT scanIntra-procedure

Change in blood volume (cm3) measured between stability scan and end of treatment scan.

Comparison of patient outcome between groups at as measured by the Glasgow Coma Scale, extended Glasgow Outcome Scale, modified Rankin Scale.0-30 days post discharge from hospital

Defined as the comparison of patients outcomes between the three groups as measured by Glasgow Coma Scale, extended Glasgow Outcome Scale, and modified Rankin Scale.

Secondary Outcome Measures
NameTimeMethod
Procedural SuccessIntra-Procedural

Less than or equal to 30% residual clot burden in the ventricular system

Technical SuccessIntra-Procedural

Percent obstruction of the IRRAflow catheter and EVD catheter

Safety - Catheter misplacementIntra-Procedural

Measurement of if the catheter needs to be re-inserted or re-positioned.

Safety - InfectionIntra-Procedural

Comparison of rate of infection as measured by routine cerebrospinal fluid (CSF) analysis

Safety - Bleeding eventsIntra-Procedural

Comparison of new bleeding events on routine neuroimaging

Trial Locations

Locations (1)

Helsinki University

🇫🇮

Helsinki, Finland

© Copyright 2025. All Rights Reserved by MedPath